OP0076 L-ARGININE REPROGRAMS OSTEOCLAST PURINE METABOLISM AMELIORATING BONE LOSS IN RHEUMATOID ARTHRITIS release_ewxww3qfsbg23do6iw6l2js3ei

by S. Cao, R. Song, X. Meng, K. Kachler, M. Fuchs, X. Meng, Y. Li, V. Taudte, M. Kunz, U. Schloetzer-Schrehardt, U. Schleicher, X. Chen (+2 others)

Published in Annals of the Rheumatic Diseases by BMJ.

2022   Volume 81, Issue Suppl 1, p52.1-52

Abstract

<jats:sec><jats:title>Background</jats:title>Bone erosion is a clinical feature of rheumatoid arthritis related to disease severity and poor functional prognosis. Excessive osteoclast differentiation and insufficient osteoblast function are the main reasons for the erosive process in RA. Our previous investigation indicated that L-arginine supplementation not only diminished arthritic inflammation in the serum-induced arthritis (K/BxN) model but also decreased inflammatory joints osteoclast numbers (1).</jats:sec><jats:sec><jats:title>Objectives</jats:title>In the present study, we aim to investigate the metabolic action of L-arginine supplementation in RA, especially on periarticular bone erosion and systemic bone loss. We plan to depict the metabolic features of TNFα induced inflammatory osteoclasts after <jats:italic>in vitro</jats:italic> L-arginine supplementation.</jats:sec><jats:sec><jats:title>Methods</jats:title>Three murine arthritis models (serum-induced arthritis (K/BxN) model, collagen-induced arthritis model, and hTNFtg mice model) were analysed in this study. L-arginine was supplemented within the drinking water after the onset of arthritis. Bone parameters for axial skeleton (spine) and peripheral skeleton (tibia) from the respective group were quantified by μCT. HE and TRAP staining were performed to address further the erosion area and osteoclast numbers in periarticular sites. <jats:italic>In vitro</jats:italic> osteoclast differentiation was conducted with or without L-arginine treatment, in the presence or not of TNFα activation. Seahorse and SCENITH analyses were adopted to delineate the metabolic features. JC-1 staining and transmission electron microscopy (TEM) were used to depict the mitochondria metabolism. RNA-seq and mass spectrometry (MS) were performed to investigate the underlying molecular mechanism.</jats:sec><jats:sec><jats:title>Results</jats:title>Inflammation was diminished in all three arthritis models after L-arginine supplementation with a significant reduction in arthritic score. Moreover, an amelioration of periarticular bone erosion, systemic bone loss, and decreased osteoclast numbers in periarticular sites were observed in arthritic mice after L-arginine treatment. L-arginine also inhibited osteoclastogenesis <jats:italic>in vitro</jats:italic>, particularly under TNFα activation. Seahorse and SCENITH analyses indicated TNFα promoted glycolysis while blocking mitochondria-driven oxidative phosphorylations (OXPHOS) in pre-osteoclasts. Meanwhile, JC-1 staining and TEM images also showed that TNFα decreased mitochondria membrane potential and prompted damage of mitochondria. Surprisingly, L-arginine rescued the TNFα inhibition of OXPHOS while promoting ATP production.RNA-seq and MS data confirmed the boost of OXPHOS after L-arginine treatment under TNFα activation. To interfere with OXPHOS, L-arginine inhibited cJun thus altered arginase-1 and arginase-2 expression. Moreover, the increased ATP in L-arginine treated cells facilitated purine metabolism, especially the production of inosine and hypoxanthine, contributing to the inhibition of osteoclastogenesis. Increasing Adenosine deaminase (ADA) is essential for the production of inosine and hypoxanthine due to the decreased inhibitory regulation of the transcription factor c-Jun.</jats:sec><jats:sec><jats:title>Conclusion</jats:title>These data strongly demonstrated that L-arginine ameliorates bone erosion in RA through metabolic reprogramming and perturbation of purine metabolism in osteoclasts. L-arginine might therefore benefit RA therapy by reducing joint inflammation and also ameliorating bone destruction.</jats:sec><jats:sec><jats:title>References</jats:title>[1]Hannemann, Nicole, et al. "Transcription factor Fra-1 targets arginase-1 to enhance macrophage-mediated inflammation in arthritis." The Journal of clinical investigation 129.7 (2019): 2669-2684.</jats:sec><jats:sec><jats:title>Disclosure of Interests</jats:title>Shan Cao: None declared, Rui Song: None declared, Xianyi Meng: None declared, Katerina Kachler: None declared, Maximilian Fuchs: None declared, Xinyu Meng: None declared, Yixuan Li: None declared, Verena Taudte: None declared, Meik Kunz: None declared, Ursula Schloetzer-Schrehardt: None declared, Ulrike Schleicher: None declared, Xiaoxiang Chen Speakers bureau: AbbVie, Roche and Novartis, Georg Schett Speakers bureau: AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, Roche and UCB, Aline Bozec: None declared.</jats:sec>
In application/xml+jats format

Archived Files and Locations

application/pdf  162.6 kB
file_442rol4ubndbrodpo6zgwkkrgy
ard.bmj.com (publisher)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2022-05-23
Language   en ?
Container Metadata
Not in DOAJ
In Keepers Registry
ISSN-L:  0003-4967
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 1279f0bc-f200-437b-a970-f8c3031a2bd0
API URL: JSON